EIK1001 + pembrolizumab + pemetrexed + carboplatin

A combination therapy consisting of EIK1001 (a systemically administered small molecule co-agonist of toll-like receptor 7 and toll-like receptor 8), pembrolizumab (an anti-PD-1 immune checkpoint inhibitor antibody), pemetrexed (an antifolate antineoplastic agent), and carboplatin (a platinum-based chemotherapy). EIK1001 is being developed as an immunomodulatory agent to stimulate myeloid and plasmacytoid dendritic cells, thereby activating T-cell responses against tumors. This combination is being studied as a first-line treatment for advanced (stage 4) non-small cell lung cancer (NSCLC), specifically in patients who have not previously received systemic therapy for advanced disease. Pembrolizumab potentiates T-cell-mediated immune response against tumors by blocking PD-1, while pemetrexed and carboplatin provide cytotoxic effects against rapidly dividing cancer cells.

Other names

pembrolizumabpemetrexedcarboplatin